1, Tianyin Holdings 000829:
In terms of ROE, from 2017 to 2020, respectively, 9.69%, -8.38%, 2.06%, 7.63%. The future cross-border intermingling with the smart home, the Internet of cars, industrial Internet, etc. will be the development trend, artificial intelligence, industrial Internet of things, biotechnology, big health and other directions will become the market hotspot in 2017, the smartphone market will also maintain a relatively strong demand, which will give the cell phone distribution industry to bring sustained development opportunities.
2, Jinhe Biological 002688:
In terms of ROE, from 2017 to 2020, respectively, 7.2%, 10.24%, 10.45%, 7.13%. in July 2015, the company to the holding bioproducts company to provide 148 million yuan of borrowing for the acquisition of Hangzhou recommend amount of veterinary biological products company 33% equity. The main business of the recommended amount of biological production of veterinary vaccines, poultry vaccines and so on.
3, open energy health 300272:
In terms of ROE, from 2017 to 2020, respectively, 7.9%, 34.79%, 8.49%, 2.22%. Participating (16.48%) company original energy group main autologous cell storage, and Ming code biotechnology in genetic testing, immune anti-aging, cell therapy, etc., the latter is a subsidiary of WuXi AppTec, has the international leading comprehensive integration of genetic medicine capabilities, including comprehensive sequencing capabilities based on CLA accredited laboratories, the world's leading gene sequencing analysis system, etc.; 17 years of the relevant revenue 41,048,900, accounting for 5.80%.
4, Tibet Pharmaceuticals 600211:
In terms of ROE, from 2017 to 2020, respectively, 14.62%, 10.07%, 13.49%, 15.09%. After years of unremitting efforts, the company has built a national enterprise technology center, three GMP-compliant drug production bases, a GAP-compliant planting base for Tibetan medicinal materials and a nationwide marketing network, with products covering the fields of biologics, Tibetan medicines, traditional Chinese medicines and chemical medicines, which lays the foundation for the company's sustainable development.
5, Haohai Biotechnology 688366:
In terms of ROE, from 2017 to 2020, respectively, 12.2%, 12.17%, 9.26%, 4.2%. The company is a scientific and technological innovative enterprise applying biomedical material technology and genetic engineering technology for the research, development, production and sales of medical devices and pharmaceuticals, and has completed the industry reorganization of absorbable biomedical materials represented by medical sodium hyaluronate/sodium vitrate and medical chitosan, and realized the industrialization of the innovative genetic engineering drug Recombinant Human Epidermal Growth Factor.